Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>UBS: INNOVENT BIO (01801.HK) Maintains 2027 Sales Target; Rating Buy
Recommend 10 Positive 14 Negative 2 |
||||
|
||||
|
During its 2026 Greater China Conference (GCC), investors focused on the sales performance of INNOVENT BIO (01801.HK)'s products in the China market, as well as the R&D progress of its key candidate IBI363 (PD-1/IL-2a) developed in collaboration with Takeda Pharmaceutical, UBS released a research report saying. INNOVENT BIO is confident in its 2025 sales performance, driven by both of its oncology and cardiovascular products, the report added. The Company maintained its target of achieving RMB20 billion product sales in 2027, and remained committed to its R&D objectives, aiming to advance five candidates into global multicenter randomized controlled trials in 2030. Therefore, UBS rated INNOVENT BIO at Buy, with a target price of $137.4. AAStocks Financial News Website: www.aastocks.com |
||||
Copied to Clipboard
 |
||||
